| Followers | 41 |
| Posts | 2281 |
| Boards Moderated | 0 |
| Alias Born | 08/20/2010 |
Thursday, April 30, 2026 10:50:56 PM
It mentions without costs to either party, but I guess a settlement still could be in there but not released, need Hoffman to chime in on X
WHEREAS, by letter dated April 30, 2026, Plaintiff Northwest Biotherapeutics, Inc.
(“NWBO”) and Defendant Canaccord Genuity LLC (“Canaccord”) have executed a settlement
agreement in which NWBO has agreed to dismiss with prejudice all claims asserted against
Canaccord in the above-captioned action, without costs to any party;
WHEREAS, NWBO and Canaccord have jointly moved by letter for dismissal of all claims
asserted against Canaccord pursuant to Federal Rule of Civil Procedure 41(a)(2);
WHEREAS, the Court finds the terms of dismissal to be proper pursuant to Federal Rule
of Civil Procedure 41(a)(2);
It is hereby ORDERED that all claims asserted against Canaccord in the above-captioned
action are dismissed with prejudice, without costs to any party.
IMO Canaccord was the weakest of all in the 208 outline.
WHEREAS, by letter dated April 30, 2026, Plaintiff Northwest Biotherapeutics, Inc.
(“NWBO”) and Defendant Canaccord Genuity LLC (“Canaccord”) have executed a settlement
agreement in which NWBO has agreed to dismiss with prejudice all claims asserted against
Canaccord in the above-captioned action, without costs to any party;
WHEREAS, NWBO and Canaccord have jointly moved by letter for dismissal of all claims
asserted against Canaccord pursuant to Federal Rule of Civil Procedure 41(a)(2);
WHEREAS, the Court finds the terms of dismissal to be proper pursuant to Federal Rule
of Civil Procedure 41(a)(2);
It is hereby ORDERED that all claims asserted against Canaccord in the above-captioned
action are dismissed with prejudice, without costs to any party.
IMO Canaccord was the weakest of all in the 208 outline.
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
